MCKINNEY, Texas– StatLab Medical Products (“StatLab” or “the Company”), a developer and manufacturer of diagnostic supplies and equipment, is pleased to announce that its Board of Directors has appointed Sung-Dae (Dae) Hong as Chief Executive Officer (CEO) and Board Member, effective August 28, 2023. Joe Bernardo, Executive Chairman and Linden Operating Partner, has been serving as Interim CEO and will continue in his role as Board Chairman.
“The Board and I are confident that Dae is not only an excellent fit to lead our global business, but also that his dynamic leadership will ignite transformation in the organization around him,” stated Joe. “With two strategic acquisitions completed and a strong, collaborative leadership team in place, we believe we’re on track to become a differentiated leader in the anatomical pathology industry. Dae’s experience in driving strategic growth through manufacturing and M&A aligns well with the opportunity facing the Company.”
Dae brings over twenty years of global strategy and general management experience to StatLab. Most recently, Dae served as President of Laboratory Products at Thermo Fisher Scientific where he oversaw a diversified global business with over twenty manufacturing sites serving life sciences and diagnostics. Prior to that, he held multiple Vice President and General Manager roles and began his tenure at Thermo Fisher as the Head of Corporate Strategy. Dae spent the first decade of his career as a management consultant at Bain & Company in Australia, Korea, and the U.S., where he led projects on growth strategy, M&A, and commercial due diligence.
“I am incredibly honored to join StatLab and to partner with this talented team with a shared goal of delivering value to our customers, stakeholders, and ultimately, each other, as we strive to build a global organization that recognizes and celebrates growth, impact, and progress in everything we do,” said Dae. “I look forward to working with Joe, the Board, and our sponsors, Audax Private Equity and Linden Capital Partners, to realize the Company’s full potential over the coming years. I’m excited as we embark on our next phase of growth.”
